Prednisolone for 12 versus 6 months for pulmonary sarcoidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study compares two treatment durations (6 months vs 12 months) of the steroid prednisolone for people with sarcoidosis affecting the lungs. The goal is to see if a shorter course works as well as a longer one, which might reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with sarcoidosis (confirmed by biopsy or cell sample) that involves the lungs or lymph nodes in the chest.
- You have symptoms needing treatment, or your lung function is below 80% of expected, or you have sarcoidosis affecting another organ that needs steroids.
- Your symptoms started within the last 2 years.
- You have not taken prednisolone (or similar) at a dose above 15 mg per day for more than 3 weeks in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if people with stable sarcoidosis can safely lower their corticosteroid dose over time. It may help reduce side effects from long-term steroid use.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests whether sirolimus, a medicine that calms the immune system, can improve skin sarcoidosis on the face. It may help people whose skin symptoms are moderate to severe and haven't improved with other treatments.
This study looks at how the immune system works in people with sarcoidosis. It may help researchers find better ways to diagnose or treat the disease in the future.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
Hear when a new Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.